Edition:
United States

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

78.34USD
4:01pm EDT
Change (% chg)

$0.73 (+0.94%)
Prev Close
$77.61
Open
$78.23
Day's High
$79.17
Day's Low
$78.11
Volume
2,278,688
Avg. Vol
1,519,183
52-wk High
$100.23
52-wk Low
$73.90

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Overall

Beta: 1.03
Market Cap(Mil.): $114,733.40
Shares Outstanding(Mil.): 1,478.33
Dividend: 1.07
Yield (%): 5.51

Financials

  ABBV.N Industry Sector
P/E (TTM): 21.95 32.81 37.60
EPS (TTM): 3.54 -- --
ROI: 11.45 12.52 12.15
ROE: -- 13.83 17.02

AbbVie appeals $493 million FTC win over 'sham' AndroGel litigation

AbbVie Inc is urging a federal appeals court to overturn a decision that found the pharmaceutical company and a partner owed $493 million for using so-called "sham" litigation to maintain an illegal monopoly over the testosterone replacement drug AndroGel.

Jun 06 2019

BRIEF-Abbvie Presents Data From Venetoclax Chemotherapy-Free Combination Regimen For Patients With Previously Untreated Chronic Lymphocytic Leukemia

* ABBVIE PRESENTS DATA FROM VENETOCLAX CHEMOTHERAPY-FREE COMBINATION REGIMEN FOR PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA

Jun 04 2019

AbbVie halts enrollment after brain cancer trial misses goal, shares fall

AbbVie Inc said on Friday it has halted enrollment of patients in all ongoing studies testing its brain cancer treatment after the drug failed to meet the main goal in a late-stage trial.

May 17 2019

UPDATE 1-AbbVie halts enrollment after brain cancer trial misses goal, shares fall

May 17 AbbVie Inc said on Friday it has halted enrollment of patients in all ongoing studies testing its brain cancer treatment after the drug failed to meet the main goal in a late-stage trial.

May 17 2019

AbbVie halts patient enrollment after brain cancer trial misses goal

May 17 AbbVie Inc said on Friday it has halted enrollment of patients in all ongoing studies testing its brain cancer treatment after the drug failed to meet the main goal in a late-stage trial.

May 17 2019

BRIEF-Abbvie Announces FDA Approval Of Venclexta For Previously Untreated Chronic Lymphocytic Leukemia Patients

* ABBVIE ANNOUNCES US FDA APPROVAL OF VENCLEXTA® (VENETOCLAX) AS A CHEMOTHERAPY-FREE COMBINATION REGIMEN FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS

May 15 2019

AbbVie raises profit forecast, but Humira concerns weigh on shares

AbbVie Inc's better-than-expected quarterly profit and revenue and raised full-year earnings forecast failed to impress investors who focused on the uncertainty around its blockbuster drug Humira as it struggles against cheaper rivals.

Apr 25 2019

UPDATE 2-AbbVie raises profit forecast, but Humira concerns weigh on shares

April 25 AbbVie Inc's better-than-expected quarterly profit and revenue and raised full-year earnings forecast failed to impress investors who focused on the uncertainty around its blockbuster drug Humira as it struggles against cheaper rivals.

Apr 25 2019

AbbVie says Humira rivals from Biogen, Amgen most aggressive so far

AbbVie Inc's Chief Executive Officer Richard Gonzalez said on a conference call that rivals Biogen Inc and Amgen Inc had been the most aggressive in Europe with their biosimilar versions of its blockbuster drug Humira.

Apr 25 2019

AbbVie says Humira rivals from Biogen, Amgen most aggressive so far

April 25 AbbVie Inc's Chief Executive Officer Richard Gonzalez said on a conference call that rivals Biogen Inc and Amgen Inc had been the most aggressive in Europe with their biosimilar versions of its blockbuster drug Humira.

Apr 25 2019

Earnings vs. Estimates